RE:BC competition Trodelvy is a chemotherapy- ADC acquired through Gilead's acquisition of Immunomedics for USD$21 Billion, and whose competition is AstraZeneca / Daiichi's Enhertu. They work by delivering chemotherapy directly to the cancer cell. - far different from ONCY's pelareorep in combination with immune checkpoint hinibitors.